Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has approved issue of duplicate share certificates requests in lieu of the original share certificates reported lost/misplaced. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Judicial pronouncement by the Hon''ble National Company Law Tribunal, Mumbai bench, approving the Scheme of Arrangement ("Scheme") between Sanofi India Limited and Sanofi Consumer Healthcare India Limited ("NCLT Order"). Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company will hold an investor / analysts call on Financial Results for the Quarter ended 31st March 2024 on 16th May 2024 at 2:00 p.m. Kindly refer to the attachment for details of the call. Sanofi India Ltd - 500674 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sanofi Launches Diabetes Drug Soliqua In India
The company introduced the medication after receiving the marketing authorisation from the Central Drugs Standard Control Organization earlier last year. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, We would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s). Sanofi India Ltd - 500674 - Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Statements (Standalone & Consolidated) For The Quarter Ended 31St March 2024
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2024 ,inter alia, to consider and approve the Unaudited Financial Statements (Standalone & Consolidated) for the Quarter ended 31st March 2024. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
The Notice of the Annual General Meeting and E-Voting information of the Company published today i.e. 23rd April 2024 , in newspapers, Business Standard and Sakal. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s). Sanofi India Ltd - 500674 - Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for the year 2023